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ORIGINAL ARTICLE
Respiratory Syncytial Virus Disease Severity Is Associated with
Distinct CD81 T-Cell Proﬁles
David T. Siefker1, Luan Vu1, Dahui You2,3, Andrew McBride2, Ryleigh Taylor2, Tamekia L. Jones2,3,4,
John DeVincenzo2,3, and Stephania A. Cormier1
1

Department of Biological Sciences, College of Science, and Department of Comparative Biomedical Sciences, School of Veterinary
Medicine, Louisiana State University, Baton Rouge, Louisiana; 2Department of Pediatrics, and 4Department of Preventive Medicine,
University of Tennessee Health Science Center, Memphis, Tennessee; and 3Children’s Foundation Research Institute, Le Bonheur
Children’s Hospital, Memphis, Tennessee
ORCID ID: 0000-0002-6050-6172 (S.A.C.).

Abstract
Rationale: Respiratory syncytial virus (RSV) causes signiﬁcant

morbidity and mortality in infants worldwide. Although T-helper
type 2 (Th2) cell pathology is implicated in severe disease, the
mechanisms underlying the development of immunopathology are
incompletely understood.
Objectives: We aimed to identify local immune responses associated

with severe RSV in infants. Our hypothesis was that disease severity
would correlate with enhanced Th2 cellular responses.
Methods: Nasal aspirates were collected from infants hospitalized

with severe (admitted to the pediatric ICU) or moderate (maintained
in the general ward) RSV disease at 5 to 9 days after enrollment. The
immune response was investigated by evaluating T-lymphocyte
cellularity, cytokine concentration, and viral load.
Measurements and Main Results: Patients with severe disease
had increased proportions of CD8 (cluster of differentiation 8)positive T cells expressing IL-4 (Tc2) and reduced proportions of
CD81 T cells expressing IFNg (Tc1). Nasal aspirates from patients
with severe disease had reduced concentrations of IL-17. Patients
with greater frequencies of Tc1, CD81 T cells expressing IL-17
(Tc17), and CD41 T cells expressing IL-17 (Th17) had shorter
durations of hospitalization.

Conclusions: Severe RSV disease was associated with distinct T-cell
proﬁles. Tc1, Tc17, and Th17 were associated with shorter hospital
stay and may play a protective role, whereas Tc2 cells may play a
previously underappreciated role in pathology.
Keywords: RSV; infant; adaptive; immunity

At a Glance Commentary
Scientiﬁc Knowledge on the Subject: Most infants with
respiratory syncytial virus are infected by their second birthday.
Despite known risk factors, such as prematurity and congenital
heart disease, most hospitalized infants are previously healthy.
The mechanisms underlying the immunopathology of severe
disease are incompletely understood.
What This Study Adds to the Field: Severe respiratory

syncytial virus disease was associated with increased IL-4–
expressing CD8 (cluster of differentiation 8)-positive T cells
and reduced IFNg–expressing T cells in nasal aspirates. IL-17
concentration in nasal aspirates was reduced in patients with
severe disease, and patients with lower frequencies of IL-17–
producing T cells had longer durations of hospitalization.
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Table 1. Patient Demographics and Clinical Characteristics

Characteristic
Age at admission, d, median (range)
Birthweight, g, median (range)
Sex, n (%)
F
M
Race, n (%)
White
African American and Hispanic
Birthplace, n (%)
Neonatal ICU
Well-baby nursery
Premature, n (%)
No
Yes
Gestational age, wk, median (range)
Breastfed, n (%)
No
Yes
Exposure to tobacco*, n (%)
No
Yes
Daycare, n (%)
No
Yes
Delivery, n (%)
Cesarean
Vaginal
Family history of asthma, n (%)
No
Yes
Oxygen supplementation, n (%)
No
Yes
Mechanically ventilated, n (%)
No
Yes
RSV strain†, n (%)
A
B
LOS, d, median (range)
Duration of fever, d, median (range)
Duration of congestion, d, median (range)
Duration of increased work of breathing, d, median
(range)
Duration of cough, d, median (range)
RSV viral load†, log TCID50/ml, median (range)

Moderate
n = 38

Severe
n = 24

69 (13–362)
2,977 (794–4,139)

87 (11–357)
2,821 (1,219–4,309)

14 (37)
24 (63)

6 (25)
18 (75)

7 (18)
31 (82)

10 (42)
14 (58)

11 (29)
27 (71)

10 (42)
14 (58)

P Value
0.749
0.5355
0.4092
0.0779
0.4097
0.4286

24 (63)
14 (37)
38 (24–41)

12 (50)
12 (50)
36.5 (29–40)

20 (53)
18 (47)

7 (29)
17 (71)

28 (74)
10 (26)

18 (75)
6 (25)

32 (84)
6 (16)

18 (75)
6 (25)

14 (37)
24 (63)

9 (38)
15 (62)

14 (37)
24 (63)

15 (63)
9 (37)

11 (29)
27 (71)

0 (0)
24 (100)

38 (100)
0 (0)

8 (33)
16 (67)

16
18
5
1
4
2

12
7
15
1
3
2

0.3842
0.1139
1
0.5111
1
0.0683
0.0043
<0.0001
0.39

(47)
(53)
(2–11)
(0–5)
(1–14)
(0–14)

4 (1–10)
6.29 (3.73–7.63)

(63)
(37)
(7–103)
(0–6)
(0–14)
(0–6)

3 (0–14)
6.47 (5.05–7.71)

<0.0001
0.8185
0.4492
0.4043
0.3343
0.3404

Definition of abbreviations: LOS = length of stay; RSV = respiratory syncytial virus; TCID50/ml = 50% tissue culture infectious dose per milliliter.
Patient demographics and clinical information by pediatric ICU status. Statistical significance was determined by Fisher’s exact test for categorical data
and Mann Whitney test for continuous data. No adjustment was made for multiple testing. P values for continuous data were computed by Mann-Whitney
test. P values for categorical data were computed by Fisher’s exact test. Bold indicates P , 0.05.
*Any household member smokes.
†
Unknown data not accounted for in analyses.

Respiratory syncytial virus (RSV) is the number
one cause of lower respiratory infections in
children (1) and hospitalization with severe
RSV disease in infancy is linked to asthma
development later in life (2). There are no
vaccines or speciﬁc therapeutics available, and
prophylactic treatment with palivizumab is
approved for high-risk infants only (3).
Although there are known risk factors for
326

severe RSV disease, such as prematurity,
,6 months of age upon initial infection, and
congenital heart disease, the majority of infants
who are hospitalized are previously healthy
without known risk factors (4). Studies have
suggested a role for immune dysfunction in
RSV disease severity. Nasal lavages of infants
with RSV bronchiolitis exhibit a greater
IL-4/IFNg ratio compared with infants

without RSV bronchiolitis (5), suggesting a
role for T-helper type 2 (Th2) (CD4 [cluster of
differentiation 4]-positive IL-41 T cells) in
immunopathology. Disease severity in infants
hospitalized with RSV has been shown to
correlate with the level of immunoregulatory
IL-10–expressing B cells, which dampen
protective Th1 responses, in the
nasopharyngeal aspirate (6). Nasopharyngeal
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Figure 1. Patients with severe disease have a CD8 (cluster of differentiation 8)-skewed T-cell
response. Nasal aspirates from infants collected 1 week after enrollment were analyzed by flow
cytometry. (A and B) The percentages of CD41 and CD81 T cells (A) and the ratio of CD81/CD41
T cells (B) are compared between patients with moderate disease (n = 31) and patients with severe
disease (n = 16). **P , 0.01 by bivariate analysis.

aspirates have also been shown to contain
enhanced proinﬂammatory cytokines such as
IL-6 and IL-8 (7–9), which may contribute
to the development of pathogenic CD41
expressing IL-17 (Th17) responses.
Furthermore, infants hospitalized with a severe
episode of RSV disease maintain high levels
of proinﬂammatory cytokines in their
nasopharyngeal aspirates 1 year after
hospitalization, with 85% of infants suffering
at least one wheezing incident (10). Despite
strong evidence that severe RSV disease is
caused by a dysfunctional immune response
and animal studies that suggest a role for
Th2 cells in immunopathology, there have
been few studies looking at the cellular
immune response to RSV in the nasal
mucosa of human infants.
Here, for the ﬁrst time, we present data
comparing the mucosal T-cell immune
responses of infants hospitalized with RSV
disease of varying severity. We tested the
hypothesis that patients admitted to the
pediatric ICU (PICU; severe) would have a
greater proportion of Th2 cells in their nasal
aspirates compared with patients admitted
to the general ward (moderate). This study
reveals that RSV disease severity is associated
with a speciﬁc T-cell proﬁle and that CD81
T cells expressing IL-4 (Tc2) cells may play
an important, underappreciated role in the
development of RSV immunopathology.

Methods
Study Design

Infants hospitalized with a positive RSV
quantitative PCR result in Le Bonheur

Children’s Hospital, Memphis, Tennessee,
during the respiratory seasons of 2014 to
2017 were enrolled in this study. Patients
who were admitted to or transferred to the
PICU within 10 days of hospital admission
were deﬁned as having severe disease, while
those admitted to the general ﬂoor were
deﬁned as having moderate disease.
Nasal aspirates were collected from 62
patients at day of enrollment for viral load
determination and between 5 and 9 days
after enrollment for ﬂow cytometry and
cytokine analysis. At this later time point,
some patients had been discharged and
returned to the hospital for sample
collection. Of the 62 patients who provided
samples up to this time point, 24 patients
had disease severe enough for admission
to the PICU and 38 patients with
moderate disease were maintained on the
general ward (see Figure E1 in the online
supplement).
Sample Collection

Nasal aspirates were collected by trained
study personnel using a standardized
method described previously (11). Cell and
supernatant isolation are described in the
online supplement.
Flow Cytometry

Cell staining is described in detail in the online
supplement. Signature cytokine expression
was used to classify nasal aspirate T cells, and
gating on cytokine positive populations
was set based on ﬂuorescence minus one
controls (see Figures E2 and E3). Within the
live CD31CD41 population, T cells were
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Real-Time RT-PCR

Viral RNA was extracted from cell-free
fractions of nasal aspirates collected on
the day of enrollment using QIAamp
Viral RNA kit (Qiagen). Viral load was
interpolated by qRT-PCR from a standard
curve produced from an RSV stock at
known concentration in 50% tissue
culture infectious dose per milliliter.
Details are provided in the online
supplement.
Multiplex Cytokine Analysis

Cell-free supernatants from nasal aspirates
were evaluated for IFNg, IL-4, IL-13, and
IL-17A concentrations using the Luminex
technology multiplex cytokine kit, Milliplex
Human High Sensitivity T-cell Panel
(EMD Millipore) with a BioPlex 200
instrument (Bio-Rad). Samples with
cytokine concentrations below the limit of
detection of the assay were replaced by a
value equal to the limit of detection divided
by the square root of 2 (12).
Statistical Analysis

Frequencies and percentages were used to
summarize categorical data, whereas median
and interquartile ranges were used to describe
continuous data. Comparison of patient
demographics, clinical characteristics, and
cellular and cytokine responses in nasal
aspirates were tested using Fisher’s exact test
for categorical data and the Mann-Whitney
test for continuous data. Luminex
coefﬁcients were computed to examine the
association between clinical data. All data
were considered statistically signiﬁcant at
P , 0.05. Bivariate analysis was used to
determine statistical differences in T-cell
subsets between patients with moderate
disease and patients with severe disease.
Statistical analyses were performed using
GraphPad Prism version 6.07 for Windows
and SAS v9.3.
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Figure 2. Patients with severe disease have a greater frequency of CD8 (cluster of differentiation 8)-positive T cells expressing IL-4 (Tc2) and reduced
frequency of CD81 T cells expressing IFNg (Tc1) than patients with moderate disease. A Boolean analysis was done of cytokine expression in T cells in
nasal aspirates of patients with moderate (n = 31) and severe respiratory syncytial virus disease (n = 16). (A) CD31 CD81 T cells (*P , 0.05 by bivariate
analysis) and (B) CD31 CD41 T cells. (C) Spearman’s correlation coefficients were determined between clinical characteristics and T-cell subsets (n = 47
patients). (D) Spearman’s correlation coefficients were determined between viral load and T-cell subsets. At day of enrollment (n = 42 patients) the viral
load could not be determined owing to lack of samples for 5 patients for whom T-cell frequency is known. At 5 to 9 days after enrollment (n = 36 patients)
viral load could not be determined owing to lack of samples for 8 patients and was undetectable in samples for 3 patients. Dotted lines represent the 95%
confidence interval. Only significant correlations are shown. P , 0.05 by Spearman’s correlation coefficient. Tc17 = CD8+ T cells expressing IL-17; TCID50/
ml = 50% tissue culture infectious dose per milliliter; Th17 = CD4+ T cells expressing IL-17.

Results
Characteristics of the Study
Population

As expected, infants with severe disease were
more likely to require supplemental oxygen
(P = 0.0043) or mechanical ventilation
(P , 0.0001) compared with patients with
moderate disease (Table 1). Furthermore,
patients with severe disease required a
signiﬁcantly longer length of hospital
stay (median, 15 d) compared with patients
with moderate disease (median, 5 d;
P , 0.0001). Importantly, there was no
328

difference in symptom duration (fever,
congestion, increased work of breather,
or cough) before enrollment between
patients with severe disease and patients
with moderate disease.
Severe Disease Is Associated with
Type 2–Skewed CD8 T-cell Response

This study aimed to characterize the
mucosal T-cell response in infants
hospitalized with RSV. Our cohort of infants
was enrolled at a median of 2 to 3 days after
symptom onset (see Table 1); therefore, we
chose to investigate T-cell proﬁles in

patients at 5 to 9 days after enrollment.
We ﬁrst compared the frequencies of
CD31CD41 and CD31CD81 T cells in
nasal aspirates between patients
with moderate disease and patients with
severe disease. Fifteen patients (seven
moderate and eight severe) were excluded
from ﬂow cytometry analysis due to low
recovery of nasal aspirate cells. Patients with
severe disease had a signiﬁcantly higher
proportion of CD81 T cells (median, 78.05%)
compared with patients with moderate
disease (median, 56.4%; P = 0.0017)
(Figure 1A). Additionally, patients with severe
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Figure 3. Patients with severe disease have a type 2–skewed T-cell response. (A) Ratio of
IL-41/IFNg1 T cells, (B) ratio of CD81 (cluster of differentiation 8–positive) T cells expressing IL-4
(Tc2)/CD81 T cells expressing IFNg (Tc1), and (C) ratio of Th2/Th1 in nasal aspirates from infants
with moderate and severe respiratory syncytial virus disease (n = 31) and patients with severe
disease (n = 16). *P , 0.05 by Mann-Whitney test. Th = T-helper cell.

disease had a signiﬁcantly lower frequency of
CD41 T cells (median, 14.3%) compared
with patients with moderate disease (median,
27%; P = 0.0062). Next, we evaluated
the ratio of CD81/CD41 T cells within each
patient. We found that patients with severe
disease had a greater CD81/CD41 T-cell
ratio (median, 5.63) compared with patients
with moderate disease (median, 1.9;
P = 0.0049) (see Figure 1B).
Our initial hypothesis was that severe
disease would be associated with a Th2biased cellular response in nasal aspirates.
However, patients with severe disease had
signiﬁcantly increased frequencies of Tc2
cells (median, 40.1%) compared with
patients with moderate disease (median,
14.4%; P = 0.033). Patients with severe
disease also had signiﬁcantly reduced
frequencies of Tc1 cells (median, 12.51%)
compared with patients with moderate
disease (median, 26.9%; P = 0.0261)
(Figure 2A and Table E1). An analysis of
the CD31CD41 subsets revealed an
increase in frequency of Th2 cells in
patients with severe disease (median,
14.8%) compared with patients with
moderate disease (median, 7.7%),
although this difference did not reach
signiﬁcance. Patients with moderate
disease and patients with severe disease
had similar frequencies of all other CD41
subsets (see Figure 2B). Gestational age
was positively correlated with the
frequency of Tc17 cells, whereas
birthweight was positively correlated
with the frequency of Th2 cells.
Additionally, the age at hospital
admission was positively correlated
with the frequency of Tc1 and Th17
cells (see Figure 2C). There were no

signiﬁcant correlations with the other
T-cell subsets (data not shown). Patients
with lower viral load at the day of
enrollment had greater frequencies of
Tc17 and Th17 cells. Additionally,
patients with lower viral load at 5 to
9 days after enrollment had greater
frequencies of Tc1 cells and a lower
ratio of IL-41 T cells/IFNg1 T cells
(see Figure 2D). There were no signiﬁcant
correlations between viral load and the
other T-cell subsets (data not shown).
There was a greater ratio of type 2/type 1
T cells in patients with severe disease
(median, 1.29) compared with patients
with moderate disease (median, 0.72;
P = 0.0368 by Mann-Whitney test);
however, this did not reach signiﬁcance
after adjusting for confounders
(P = 0.5758) (Figure 3A). Within the
CD81 fraction, patients with severe
disease had greater Tc2/Tc1 ratios
(median, 1.54) compared with patients
with moderate disease (median, 0.70;
P = 0.0202 by Mann-Whitney test);
however, this did not reach signiﬁcance
after adjusting for confounders
(P = 0.1672) (see Figure 3B). There was
no difference in the Th2/Th1 ratio
between patients with moderate disease
and patients with severe disease (see
Figure 3C). Further investigation
of the CD31CD81 subset revealed an
association between the level of CD8
expression and the cytokine produced.
CD31CD81 T cells diverged into
two separate populations based on CD8
expression (Figure 4). A gate around the
total CD81 population includes cells
expressing IL-4 (Tc2), IFNg (Tc1), and
IL-17 (Tc17) (see Figure 4A). However,

Siefker, Vu, You, et al.: Mucosal T-Cell Responses to RSV

Tc1, Tc17, and Th17 Cell Subsets Are
Associated with Shorter Hospital
Length of Stay

As previously described, hospital length of
stay was signiﬁcantly greater in patients
with severe disease compared with
patients with moderate disease (see
Table 1). To further investigate whether
frequencies of T-cell subsets are
associated with disease severity, we
examined whether the frequency of T-cell
subsets correlated with length of stay.
Within the CD81 compartment, Tc1 and
Tc17 subsets were negatively correlated
with length of stay (r = 20.4333;
P = 0.0023 and r = 20.3415; P = 0.0188,
respectively). In contrast, Tc2 cells were
positively correlated with length of stay;
however, this relationship did not reach
statistical signiﬁcance (r = 0.2549;
P = 0.0838) (Figure 5A). Within the CD41
compartment, Th17 cells were also
negatively correlated with length of
stay (r = 20.2955; P = 0.0437) (see
Figure 5B).
Patients with Severe Disease Have
Reduced IL-17 Concentrations in
Nasal Aspirates

We tested the hypothesis that type 2
cytokine concentrations would be greater in
the nasal aspirate supernatants of patients
with severe disease compared with patients
with moderate disease. Surprisingly, despite
greater frequency of type 2 T cells in nasal
aspirates of patients with severe disease, the
concentration of the type 2 cytokines IL-4
and IL-13 were similar among patients with
moderate disease and patients with severe
disease. There was also no difference in the
type 1 cytokine IFNg between patients with
moderate disease and patients with severe
disease. Interestingly, however, patients
with severe disease had signiﬁcantly
reduced IL-17 concentrations (median,
0.592 pg/ml) compared with patients with
moderate disease (median, 1.262 pg/ml;
P = 0.0086) (Figure 6). We also asked
whether the frequency of T-cell subsets
correlated with their signature cytokine
329
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Figure 4. Level of CD8 (cluster of differentiation 8) expression correlates with cytokine production. (A)
T cells expressing IFNg (Tc1), T cells expressing IL-4 (Tc2), and CD81 T cells expressing IL-17 (Tc17)
cells distinguished based on cytokine expression within the total CD81 gate. (B) The majority of Tc1
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CD8 expression. (C) Comparison of CD8 median fluorescence intensity in Tc1, Tc2, and Tc17 cells as
defined in A. A representative sample is shown. MFI = median fluorescence intensity.

concentrations in nasal aspirates. Within
the CD81 subset, the frequency of Tc17
cells had a positive correlation with the
concentration of IL-17 (r = 0.3092;
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P = 0.0463). In contrast, Tc1, Tc2, and all
Th subsets were not correlated with their
signature cytokine concentrations (see
Figure E4).

Many studies describe the immune response
to RSV as type 2–biased (5, 13–16). It is
controversial, however, whether the level of
type 2 cytokines (IL-4, IL-5, and IL-13) or
proportions of type 2 cytokine–producing
cells (Th2 and Tc2) are associated with
varying severity of disease. Here, we tested
the hypothesis that patients admitted to the
PICU would have a greater proportion of
Th2 cells in nasal aspirates compared with
patients admitted to the general ward.
Indeed, our results showed a greater
proportion of IL-41 T cells in patients
with severe disease; however, statistical
signiﬁcance was reached only in the CD81
fraction. In the CD41 fraction, IL-41
T cells were increased in patients with
severe disease compared with patients with
moderate disease; however, this difference
did not reach signiﬁcance. Two studies have
shown enhanced IL-4/IFNg ratios in nasal
aspirates in patients with more severe RSV
disease (5, 13). In our study there was no
difference in the IL-4/IFNg ratio, which
might be a result of the late time point after
the decline of these cytokines. Of course, we
only evaluated one time point in this study
and it is possible that the peak CD4
response has already occurred. It has been
shown that CD4 responses occur before
CD8 (17). Because patients often arrive
in the hospital days after the onset of
symptoms it is impossible to know when
the patients were infected. This ambiguity
in the time of infection could result in
analysis at a later time point dominated by
CD8 responses. Nevertheless, a pathogenic
role for CD81 T cells is also supported by
mouse models of RSV infection (18).
Depletion of CD81 cells reduces illness in
mice after primary RSV infection (19), and
adoptive transfer of an RSV-speciﬁc
cytotoxic T lymphocyte clone both
exacerbated lung pathology in mice and
mediated viral clearance (20). On the other
hand, fatal cases of RSV infection in human
infants show few lymphocytes (neither
CD81 nor CD41) by immunohistostaining
of postmortem lung tissue (21, 22).
Importantly, cytokine staining was not
performed, and it is possible that these
patients succumbed to infection before
lymphocyte recruitment. Indeed, IL-4–
expressing CD81 T cells have been found
in the blood after RSV infection, but their
proportions are negatively correlated with
disease severity (23). It is possible that a
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Figure 5. CD81 T cells expressing IFNg (Tc1), CD81 T cells expressing IL-17 (Tc17), and CD41
T cells expressing IL-17 (Th17) cell subsets are associated with shorter hospital length of stay. (A–B)
Spearman’s correlation coefficients (r) were determined between hospital length of stay and
frequency of nasal aspirate Th1 (CD31CD41IFNg1), T-helper cell type 2 (Th2) (CD31CD41IL-41),
and Th17 (CD31CD41IL-171) (A); and Tc1 (CD31CD81IFNg1), T cells expressing IL-4 (Tc2)
(CD31CD81IL-41), and Tc17 (CD31CD81IL-171) (B). n = 47 patients. Dotted lines represent
the 95% confidence interval. P , 0.05 by Spearman’s correlation coefficient.

reduction in systemic Tc2 cells in severe
RSV disease is a result of relocation to the
respiratory tract. It has been shown that
Tc2 cells induced by HIV infection have
reduced cytotoxic activity (24). Future
directions will include characterization of
the Tc2 cells found in patients with severe
RSV disease, such as activation status and
cytotoxic activity. Altogether, these results
suggest an important role for Tc2 cells in
the severity of RSV disease.
Many studies attribute IL-4 protein
detected in BAL ﬂuid, nasal aspirates, or

peripheral blood to a Th2 response (25–27).
This study reveals CD81 T cells as an
important source of IL-4 production in
RSV-infected infants. It has been shown in
mice that Th2 responses to lymphocytic
choriomeningitis virus infection cause
virus-speciﬁc CD81 T cells to switch from
IFNg production to IL-5 production (Tc1
to Tc2 switch) (28). Furthermore, these Tc2
cells mediated eosinophil recruitment to the
lungs upon lymphocytic choriomeningitis
virus peptide challenge. It is possible that in
human infants an initial Th2 response
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induces a robust Tc2 response, and both
T-cell compartments synergize to establish
severe disease.
It was also observed that Tc2 cells in
nasal aspirates of RSV patients expressed
lower levels of CD8 than Tc1 cells (see
Figure 4). Reduced CD8 expression in
T cells has been associated with activation,
reduced antigen sensitivity (29), and
reduced degranulation (30). In a macaque
model of acute simian immunodeﬁciency
virus infection, antigen-speciﬁc CD81
could also be separated into CD8high and
CD8low populations (31). Importantly, the
CD8low population produced less IFNg
compared with the CD8high population,
similar to what we observe in human
infants with RSV. Unfortunately,
production of IL-4 was not tested in this
model. However, it has been shown in mice
that IL-4 reduces RSV-speciﬁc cytolytic
activity and delays viral clearance (32). In
fact, we found reduced proportions of Tc1
cells in patients with severe disease
compared with patients with moderate
disease (see Figure 2A). Additionally, CD8
T cells activated under type 2 conditions
produce IL-4 while downregulating CD8
expression, granzyme B, and IFNg in vitro
(33). Further studies will determine
differences in the phenotypes of Tc1 versus
Tc2 cells in nasal aspirates from RSVinfected infants.
Higher frequencies of Tc2 cells and
lower frequencies of Tc1 cells were
associated with admission to the PICU in
patients hospitalized with RSV. This
prompted us to ask whether the frequencies
of T-cell subsets are also associated with the
total length of hospital stay. Indeed, Tc1,
Tc17, and Th17 frequencies were negatively
correlated with length of stay, suggesting
that these cell types and/or their effector
cytokines IFNg and IL-17 confer protection
to RSV disease (see Figure 5). Likewise,
IL-17 concentration was signiﬁcantly lower
in patients with severe disease compared
with moderate disease (see Figure 6). These
results suggest a protective effect for IL-17
and are supported by a previous study that
observed decreased IL-17 concentrations
in nasal aspirates of ventilated infants
compared with nonventilated infants at the
time of hospital discharge (34).
Although the frequency of Tc17 cells
was signiﬁcantly correlated with IL-17
concentrations in the nasal aspirates,
overall, the frequencies of T-cell subsets
were not correlated with their signature
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Figure 6. Lower IL-17 levels are observed in the nasal aspirates of patients with severe disease. Cytokine concentrations in the cell-free nasal aspirates
were compared between patients with moderate and severe respiratory syncytial virus disease. Undetectable samples were set to the limit of detection
divided by the square root of 2 (12). Cell-free nasal aspirates were not available for analysis from 3 patients with moderate disease (n = 35) and 5 patients
with severe disease (n = 19). **P , 0.01 by Mann-Whitney test.

cytokine concentrations (see Figure E4).
The lack of correlation may be due to the
time point analyzed. As previously noted, it
has been shown that IL-17 concentrations
are higher later in the course of infection in
patients with moderate disease. Indeed,
IL-17 and IFNg were detectable in the
majority of patients (88%) at 5 to 9 days
after enrollment, regardless of disease
severity. In contrast, only 47% of patients
had detectable IL-4, and 32% had detectable
IL-13 levels at this time point. Therefore, our
time point may be appropriate to compare
frequencies of T-cell subsets that express
their signature cytokines after stimulation ex
vivo but too late to detect these cytokines in
the nasal aspirate supernatant. Another
possibility that may explain the discrepancy
between the frequency of T-cell subsets and
their signature cytokine concentration in the
nasal aspirate is that the multiple cell types
may be responsible for the overall cytokine
concentration.
There are conﬂicting reports in the
literature regarding whether viral load is
associated with disease severity. Many
reports show a positive correlation between
viral load and disease severity (11, 35–37).
However, some studies report that disease
severity is not associated with viral load (13,
38, 39). Recently, it was reported that viral
load is lower in patients with severe
compared with moderate disease when
adjusted for symptom duration (40).
Discrepancies within the literature are likely
the result of differences in characterization
of disease severity, patient demographics,
variability in the time after symptom
onset that sampling occurs, sampling
method, and even method of viral load
determination. In this study, admission to
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the PICU versus general ward was not
associated with viral load at the day of
enrollment or the day of ﬂow cytometry
analysis (see Figure E5). However, patients
with lower viral load at the day of enrollment
had increased frequencies of Tc17 and Th17
cells, and patients with lower viral load at
5 to 9 days after enrollment had higher
frequencies of Tc1 and a reduced ratio of total
IL-41/IFNg1 T-cell cells (see Figure 2D).
Likewise, it has been shown in experimental
RSV infection of adults that RSV-speciﬁc
CD81 T cells are inversely correlated with
viral load (41).
We acknowledge that, in contrast to
our results, there are a number of reports
indicating a correlation between age and
disease severity. The majority of those
reports use hospitalization as the deﬁnition
of severe disease and some include children
over the age of 12 months (42–46). In
contrast, our study involved only hospitalized
infants (,1 yr of age). Additionally, 53 out of
62 (85.5%) of our patient population were less
than 6 months of age. Of the studies using the
same deﬁnition of severity (i.e., PICU versus
ward) and comparing children of similar
age, one failed to demonstrate a correlation
with age and severity (11, 47–50). We
do not understand the reasons for these
discrepancies, but we reiterate that differences
in characterization of disease severity,
differences in patient demographics,
variability in the time after symptom onset
that sampling occurs, sampling method, and
even method of viral load determination exist
across these studies and could be responsible
for the different outcomes.
This study has some limitations. This
study was performed in a predominantly
African American population. In our study,

African Americans had signiﬁcantly
reduced Tc2 cells compared with white
individuals (see Table E2). These results are
in line with a previous study showing that
African Americans in Tennessee are less
likely to be hospitalized for bronchiolitis
within the ﬁrst year of life compared with
white individuals (51). A multicenter study
that includes areas of multiple racial
backgrounds would provide a more
comprehensive picture of RSV disease
among genetically diverse populations.
Additionally, disease severity is a subjective
classiﬁcation. Here, we chose to deﬁne
severe disease as admission to the PICU.
However, the majority of patients with
moderate disease required supplemental
oxygen (71.1%). Characterization of disease
severity by PICU status could be reﬁned
further by incorporating objective clinical
parameters to determine severity. Several
severity scoring methods have been used to
categorize infants with varying disease
severity (52–59). The adoption of a single,
standardized RSV severity scoring system
would allow better comparisons between
studies performed by different groups.
Interestingly, Tc2 and Th2 cells were
signiﬁcantly higher in patients on oxygen
supplementation. Another limitation is our
small sample size. Out of 243 infants
enrolled between 2014 and 2017 over three
respiratory seasons, only 62 patients
provided samples out to the 5 to 9
days after the enrollment time point.
Furthermore, only 24 of these patients were
admitted to the PICU. Additionally, some
nasal aspirates could not be analyzed by
ﬂow cytometry due to low numbers of
live lymphocytes. Statistically signiﬁcant
differences in immune proﬁles between
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patients were found despite our small
sample size.
Conclusions

This study suggests that a speciﬁc mucosal
T-cell subset may contribute to severe RSV
disease. To our knowledge, this is the ﬁrst

study to directly evaluate cytokineproducing T cells in nasal aspirates.
These results show that RSV disease
severity is associated with a speciﬁc
immune proﬁle and suggest a role for
CD81 T cells in the development of RSV
immunopathology. n
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